<DOC>
	<DOCNO>NCT02502396</DOCNO>
	<brief_summary>The primary objective study evaluate practice pattern rivaroxaban usage invenous-thromboembolism ( VTE ) non-valvular atrial fibrillation ( NVAF ) cancer patient . The secondary objective evaluate outcome recurrent VTE , stroke bleed cancer patient rivaroxaban .</brief_summary>
	<brief_title>Rivaroxaban Utilization Treatment Prevention Thromboembolism Cancer Patients : Experience Comprehensive Cancer Center</brief_title>
	<detailed_description>This retrospective descriptive study review chart approximately375 cancer patient prescribe rivaroxaban January 1 , 2012 November 7 , 2016 UT MDACC NVAF patient prior VTE diagnosis cancer . The list patient prescribed rivaroxaban study period obtain Pharmacy Informatics . We review eligibility patient pharmacy list prescribe rivaroxaban study time-frame . The eligible patient meet inclusion/exclusion criterion identify . All available data concern demographic , clinical parameter rivaroxaban usage collect eligible patient Pharmacy Informatics , CS , Laboratory Informatics , Clinical Informatics Databases . The variables interest include demographic information , clinical parameter ( tumor type , extent disease , clinical exam finding , presence comorbidities , diagnostic assessment , treatment intervention ) , reason rivaroxaban discontinuation outcome . The confidentiality patient-specific data maintain . By use Pharmacy Informatics CS , capture patient prescribed rivaroxaban UT MDACC.This descriptive study final sample size depend available record chart review 01/01/2012 11/07/2016 .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . Age range : patient must â‰¥ 18 year . 2 . Male female patient eligible enrollment . 3 . Patients diagnose deepvein thrombosis lower upper extremity , pulmonary embolism nonvalvular atrial fibrillation . 4 . Patients must active malignancy define diagnosis cancer ( exclude basal cell squamous cell carcinoma skin ) within six month enrollment , receive treatment cancer within previous six month document recurrent metastatic cancer . 1 . Patients hemodialysis 2 . Patients valvular heart disease ( use coexist prosthetic heart valve hemodynamically significant valve disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Deep-vein thrombosis lower upper extremity</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Chart review</keyword>
	<keyword>VTE</keyword>
	<keyword>NVAF</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>